Zennova Pharmaceuticals Group is an international pharmaceutical company registered in Cayman, driven by innovative research and development. We have excellent product development technology and world-class quality products . Weprovide superior value of world-class medicines to our patients . Our strategy focus on global research and development, manufacturing in China, and serving global markets. We are focusing on four major therapeutic areas:ophthalmology, virology, cardiovascular and oncology. We currently have R&D and production facilitiesin New York, New Jersey, and Chengdu, China. Our State-of-The-Art pharmaceutical manufacturing facility located in Chengdu Tianfu International Biotown is designed to qualify US FDA, EU EMA, and China cGMP standards. It is set up to meet world-class quality standard for all dosage forms of medicines. It includes various oncology drugs, sterile eye drops products, central nervous system medicines , and other complex formulation drugs. Our products are to be sold to the US, Europe, China and other global markets.
Make every effort to build a full dosage form international preparation center, with product sales targeting the Chinese, American, and global markets
Perfectly solve the worldwide problem of replacing in vivo clinical endpoint with in vitro consistency evaluation, and successfully develop a blockbuster product for the treatment of Dry eye syndrome
Intensive cultivation and meticulous cultivation have achieved significant original technological achievements, and the world has an exclusive platform for new drug development patent technology
Zennova Pharma Group’s China facility is in production recently. Its 350,000 SQF state-of- the-art cGMP facility will support US & global markets for various of Rx products.
Zennova Pharma Group recently achieved a significant milestone by successfully completing a Series B fundraising round of over 15 million dollars.
At the start of the new year and on the morning of January 11, 2023, the groundbreaking ceremony for Zennova Pharmaceuticals’ manufacturing plant and R&D center interior construction project was held
The globally innovative LiquPuls™ new drug development technology platform can significantly improve the bioavailability and reduce the toxic side effects of all known insoluble and insoluble drug molecules. We have an international leading position in new drug screening, drug research and development, and process exploration.